Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy
This study is ongoing, but not recruiting participants.
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes
Sponsors and Collaborators: FDA Office of Orphan Products Development
Mayo Clinic
Information provided by: FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier: NCT00004407
  Purpose

OBJECTIVES: I. Determine the effect of intravenous immunoglobulin on recovery time of patients with proximal diabetic neuropathy.

II. Determine whether rate of response is dose dependent in these patients.


Condition Intervention
Diabetic Neuropathies
Drug: immune globulin

MedlinePlus related topics: Diabetic Nerve Problems
Drug Information available for: Immunoglobulins Globulin, Immune
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 75
Study Start Date: February 1998
Detailed Description:

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to treatment with low dose intravenous immunoglobulin (IVIg), high dose IVIg, or placebo. Patients must first complete baseline evaluation. Patients receive IVIg or placebo on days 1, 2, 3, and 5, biweekly at weeks 2-4, weekly at weeks 5-8, and every other week at weeks 9-12. Patients are assessed at 6, 12, 36, 52, and 104 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Diagnostically proven non-insulin dependent diabetes mellitus as defined by the following criteria: Presence of classic symptoms, such as polyuria, polydipsia, ketonuria, and rapid weight loss, together with plasma glucose elevations Elevated fasting glucose concentration on more than one occasion
  • Diagnostically proven proximal diabetic neuropathy with any of the following symptoms: Severe thigh, hip, or leg pain Greater than 20% weight loss Progressive proximal weakness in the painful leg Weakness in the contralateral lower limb Thoracic or cervical root distribution Symmetric distal polyneuropathy or autonomic neuropathy may be mild or absent

--Prior/Concurrent Therapy--

  • At least 6 months since prior immunosuppression or plasma exchange
  • No history of prior renal transplant

--Patient Characteristics--

  • Age: 18 and over
  • Performance status: Gait impairment at least grade 2
  • Hematopoietic: Not specified
  • Hepatic: Not specified
  • Renal: Creatinine no greater than 1.4 mg/dL (women) Creatinine no greater than 1.5 mg/dL (men) No history of renal failure
  • Cardiovascular: No history of cardiac failure
  • Neurologic: Normal nerve conduction studies or changes compatible with distal symmetric diabetic neuropathy or diabetic lumbosacral radioplexus neuropathy Spinal fluid cell count less than 5 cells/mm3 Normal cerebral spinal fluid cytology No structural spine disease No inherited neuropathy
  • Other: Electromyographic evidence of proximal lower limb plexus OR Radicular denervation compatible with proximal diabetic neuropathy No other systemic disease or malignancy Normal IgA levels No chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) No systemic amyloidosis No monoclonal gammopathy associated neuropathy No history of allergy to serum products No selective cervical or root involvement without lower limb weakness No evidence of secondary diabetes
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004407

Sponsors and Collaborators
Mayo Clinic
Investigators
Study Chair: Anthony J. Windebank Mayo Clinic
  More Information

No publications provided

Study ID Numbers: 199/13294, MAYOC-91596, MAYOC-FDR001358
Study First Received: October 18, 1999
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00004407     History of Changes
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
diabetic amyotrophy
diabetic lumbosacral radiculoplexus neuropathy
diabetic neuropathy
diabetic proximal neuropathy
neurologic and psychiatric disorders
rare disease

Study placed in the following topic categories:
Immunologic Factors
Diabetic Neuropathies
Rare Diseases
Diabetes Mellitus
Endocrine System Diseases
Antibodies
Neuromuscular Diseases
Mental Disorders
Immunoglobulins, Intravenous
Peripheral Nervous System Diseases
Rho(D) Immune Globulin
Endocrinopathy
Muscular Atrophy
Diabetes Complications
Immunoglobulins

Additional relevant MeSH terms:
Diabetic Neuropathies
Immunologic Factors
Nervous System Diseases
Physiological Effects of Drugs
Diabetes Mellitus
Endocrine System Diseases
Pharmacologic Actions
Antibodies
Neuromuscular Diseases
Immunoglobulins, Intravenous
Peripheral Nervous System Diseases
Diabetes Complications
Immunoglobulins

ClinicalTrials.gov processed this record on May 07, 2009